

BOSTON SCIENTIFIC CORP  
Form 8-K  
February 25, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

---

Date of Report (Date of earliest event reported): **February 23, 2016**

**BOSTON SCIENTIFIC CORPORATION**

(Exact name of registrant as specified in charter)

**DELAWARE**  
(State or other  
jurisdiction of  
incorporation)

**1-11083**  
(Commission  
file number)

**04-2695240**  
(IRS employer  
identification no.)

**300 Boston Scientific Way, Marlborough, Massachusetts**  
(Address of principal executive offices)

**01752-1234**  
(Zip code)

Registrant's telephone number, including area code: **(508) 683-4000**

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**(d) Election of Directors**

On February 23, 2016, the Board of Directors (the Board) of Boston Scientific Corporation (the Company), upon the recommendation of the Nominating and Governance Committee, increased the number of directors comprising the Board from twelve to thirteen and appointed Ellen M. Zane to be a director of the Company, filling the vacancy, to hold office until the next annual meeting of stockholders, effective April 15, 2016.

Under the Company's non-employee director compensation program (the Program), Ms. Zane will receive standard non-employee director compensation, prorated for the time period from the effective date of her appointment to the date of the Company's 2016 annual meeting of stockholders (the 2016 Annual Meeting), which includes (i) a cash retainer of \$4,698 (representing the prorated amount of the Program's annual cash retainer of \$90,000) and (ii) an equity award valued at \$9,657 (representing the prorated amount of the Program's annual grant of equity having a value of \$185,000) vesting at the end of her term. The actual number of shares to be granted to Ms. Zane will be determined on the date of grant, May 2, 2016, which is the first business day of the month following the month in which she will be appointed.

In connection with her appointment to the Board, the Company intends to enter into an indemnification agreement with Ms. Zane in substantially the same form as the Company has entered into with each of the Company's existing directors and as previously filed with the Securities and Exchange Commission.

A copy of our press release announcing the appointment of Ms. Zane is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

**Directors Not Standing for Re-election**

On February 25, 2016, the Company announced that three current members of its Board, Pete M. Nicholas, N.J. Nicholas, Jr., and Ernest Mario, Ph.D., will not stand for re-election at the Company's 2016 Annual Meeting. Mr. Pete Nicholas has served as a member of the Board since 1979. He served as Co-Chairman of the Board from 1979 to 1995, and currently serves as Chairman of the Board, a role he has held since 1995. Mr. N.J. Nicholas, Jr. has served as a member of the Board since 1994 and currently serves as the Chairman of the Nominating and Governance Committee. Dr. Mario has served as a member of our Board since 2001 and currently serves as the Chairman of the Executive Compensation and Human Resources Committee and a member of the Audit Committee. Mr. Pete M. Nicholas will continue to serve as Chairman of the Board and Mr. N.J. Nicholas, Jr. and Dr. Mario will continue to serve as directors and in their committee roles until the 2016 Annual Meeting.

The directors' decision not to stand for re-election at the 2016 Annual Meeting marks their retirement from the Board after many years of distinguished service and is not the result of any disagreement with the other Board members or with management.

## Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

On February 23, 2016, in connection with the retirement of three of our current Board members and upon the recommendation of the Nominating and Governance Committee, the Board approved a decrease in the number of directors comprising the Board from thirteen to ten, effective immediately following the 2016 Annual Meeting.

### **Item 8.01**

### **Other Events**

On February 23, 2016, in connection with Mr. Pete M. Nicholas' upcoming retirement from his role as Chairman of the Board, upon the recommendation of the Nominating and Governance Committee, the Board appointed the Company's Chief Executive Officer, Michael F. Mahoney, to serve as Chairman of the Board and current director Edward J. Ludwig to serve as Lead Independent Director, effective immediately following the 2016 Annual Meeting.

A copy of our press release announcing the appointment of Messrs. Mahoney and Ludwig is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued by Boston Scientific Corporation dated February 25, 2016.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 25, 2016

BOSTON SCIENTIFIC CORPORATION

By:

*/s/ Vance R. Brown*  
Vance R. Brown  
Vice President and Chief Corporate Counsel

**INDEX TO EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Boston Scientific Corporation dated February 25, 2016